Yongfeng Yu

机构：Shanghai Jiao Tong University, Shanghai Chest Hospital

发表论文 48 篇 · 总被引 606 次 · h-index 11

代表论文

• Cisplatin-induced Pyroptosis Enhances the Efficacy of PD-L1 Inhibitor in Small-Cell Lung Cancer via GSDME/IL12/CD4Tem Axis (2023 · International Journal of Biological Sciences · 被引 38)
• EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer (2024 · Journal of Translational Medicine · 被引 32)
• Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study (2024 · The Lancet Respiratory Medicine · 被引 21)
• Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study) (2022 · Cancer Research · 被引 10)
• Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET -amplification ( MET amp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study. (2025 · Journal of Clinical Oncology · 被引 9)
• Dacomitinib in the treatment of EGFR-mutated non-small cell lung cancer with brain metastases: an open-label, multicenter, phase II study (2025 · Lung Cancer · 被引 4)